Seeking Standardized Definitions for HLA-incompatible Kidney Transplants: A Systematic Review.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
pubmed:
3
8
2022
medline:
15
12
2022
entrez:
2
8
2022
Statut:
ppublish
Résumé
There is no standard definition for "HLA incompatible" transplants. For the first time, we systematically assessed how HLA incompatibility was defined in contemporary peer-reviewed publications and its prognostic implication to transplant outcomes. We combined 2 independent searches of MEDLINE, EMBASE, and the Cochrane Library from 2015 to 2019. Content-expert reviewers screened for original research on outcomes of HLA-incompatible transplants (defined as allele or molecular mismatch and solid-phase or cell-based assays). We ascertained the completeness of reporting on a predefined set of variables assessing HLA incompatibility, therapies, and outcomes. Given significant heterogeneity, we conducted narrative synthesis and assessed risk of bias in studies examining the association between death-censored graft failure and HLA incompatibility. Of 6656 screened articles, 163 evaluated transplant outcomes by HLA incompatibility. Most articles reported on cytotoxic/flow T-cell crossmatches (n = 98). Molecular genotypes were reported for selected loci at the allele-group level. Sixteen articles reported on epitope compatibility. Pretransplant donor-specific HLA antibodies were often considered (n = 143); yet there was heterogeneity in sample handling, assay procedure, and incomplete reporting on donor-specific HLA antibodies assignment. Induction (n = 129) and maintenance immunosuppression (n = 140) were frequently mentioned but less so rejection treatment (n = 72) and desensitization (n = 70). Studies assessing death-censored graft failure risk by HLA incompatibility were vulnerable to bias in the participant, predictor, and analysis domains. Optimization of transplant outcomes and personalized care depends on accurate HLA compatibility assessment. Reporting on a standard set of variables will help assess generalizability of research, allow knowledge synthesis, and facilitate international collaboration in clinical trials.
Sections du résumé
BACKGROUND
There is no standard definition for "HLA incompatible" transplants. For the first time, we systematically assessed how HLA incompatibility was defined in contemporary peer-reviewed publications and its prognostic implication to transplant outcomes.
METHODS
We combined 2 independent searches of MEDLINE, EMBASE, and the Cochrane Library from 2015 to 2019. Content-expert reviewers screened for original research on outcomes of HLA-incompatible transplants (defined as allele or molecular mismatch and solid-phase or cell-based assays). We ascertained the completeness of reporting on a predefined set of variables assessing HLA incompatibility, therapies, and outcomes. Given significant heterogeneity, we conducted narrative synthesis and assessed risk of bias in studies examining the association between death-censored graft failure and HLA incompatibility.
RESULTS
Of 6656 screened articles, 163 evaluated transplant outcomes by HLA incompatibility. Most articles reported on cytotoxic/flow T-cell crossmatches (n = 98). Molecular genotypes were reported for selected loci at the allele-group level. Sixteen articles reported on epitope compatibility. Pretransplant donor-specific HLA antibodies were often considered (n = 143); yet there was heterogeneity in sample handling, assay procedure, and incomplete reporting on donor-specific HLA antibodies assignment. Induction (n = 129) and maintenance immunosuppression (n = 140) were frequently mentioned but less so rejection treatment (n = 72) and desensitization (n = 70). Studies assessing death-censored graft failure risk by HLA incompatibility were vulnerable to bias in the participant, predictor, and analysis domains.
CONCLUSIONS
Optimization of transplant outcomes and personalized care depends on accurate HLA compatibility assessment. Reporting on a standard set of variables will help assess generalizability of research, allow knowledge synthesis, and facilitate international collaboration in clinical trials.
Identifiants
pubmed: 35915547
doi: 10.1097/TP.0000000000004262
pii: 00007890-202301000-00030
doi:
Substances chimiques
HLA Antigens
0
ABO Blood-Group System
0
Types de publication
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
231-253Subventions
Organisme : CIHR
ID : LSARP 273AMR
Pays : Canada
Organisme : CIHR
ID : GP1-155871
Pays : Canada
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant. 2004;4:561–568.
Sharif A, Kraus ES, Zachary AA, et al. Histologic phenotype on 1-year posttransplantation biopsy and allograft survival in HLA-incompatible kidney transplants. Transplantation. 2014;97:541–547.
Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. 2016;374:940–950.
Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant. 2014;14:1573–1580.
Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA. 2005;294:1655–1663.
Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365:318–326.
Montgomery RA, Hardy MA, Jordan SC, et al.; Antibody Working Group on the Diagnosis, Reporting, and Risk Assessment for Antibody-mediated Rejection and Desensitization Protocols. Consensus opinion from the Antibody Working Group on the Diagnosis, Reporting, and Risk Assessment for Antibody-mediated Rejection and Desensitization Protocols. Transplantation. 2004;78:181–185.
Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant. 2006;6:1841–1847.
Bagnasco SM, Zachary AA, Racusen LC, et al. Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients. Transplantation. 2014;97:440–445.
Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation. 2008;85:1046–1050.
ten Hoor GM, Coopmans M, Allebes WA. Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival. Transplantation. 1993;56:298–304.
Oldfather JW, Anderson CB, Phelan DL, et al. Prediction of crossmatch outcome in highly sensitized dialysis patients based on the identification of serum HLA antibodies. Transplantation. 1986;42:267–270.
Gupta A, Iveson V, Varagunam M, et al. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation. 2008;85:1200–1204.
Duquesnoy RJ, Marrari M. Progress report on the ASHI/CAP proficiency survey program in histocompatibility testing. II. HLA-DR, DQ serologic typing, antibody identification, and B-cell crossmatching. American Society for Histocompatibility of Immunogenetics. College of American Pathologists. Hum Immunol. 1994;39:96–105.
Zangwill S, Ellis T, Stendahl G, et al. Practical application of the virtual crossmatch. Pediatr Transplant. 2007;11:650–654.
Worsley CM, Mayne ES, Suchard MS. Luminex-based virtual crossmatching for renal transplantation in South Africa. S Afr Med J. 2011;102:40–43.
Jackson AM. The virtual crossmatch: an essential tool for transplanting sensitized patients. Clin Transpl. 2014:131–136.
Ferrari P, Fidler S, Holdsworth R, et al. High transplant rates of highly sensitized recipients with virtual crossmatching in kidney paired donation. Transplantation. 2012;94:744–749.
Ellis TM, Schiller JJ, Roza AM, et al. Diagnostic accuracy of solid phase HLA antibody assays for prediction of crossmatch strength. Hum Immunol. 2012;73:706–710.
Bingaman AW, Murphey CL, Palma-Vargas J, et al. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation. 2008;86:1864–1868.
Amico P, Hönger G, Steiger J, et al. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant. 2009;14:656–661.
Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation. 2013;95:852–858.
Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89:1095–1102.
Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242–251.
Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014;98:312–319.
Reinsmoen NL, Lai CH, Vo A, et al. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med. 2012;13:267–273.
Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–739.
Ogura K, Terasaki PI, Johnson C, et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation. 1993;56:294–298.
Magee CC, Felgueiras J, Tinckam K, et al. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center’s experience. Transplantation. 2008;86:96–103.
Leone JP, Bowers V, Baliga R, et al. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience. Clin Transpl. 2011:373–379.
Lentine KL, Graff RJ, Xiao H, et al. Flow cytometry crossmatch before kidney transplantation in contemporary practice: target cell utilization, results patterns, and associated long-term graft survival. Clin Transpl. 2008:253–266.
Kerman RH, Susskind B, Ruth J, et al. Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch? Transplantation. 1998;66:1833–1834.
Jordan SC, Vo AA. Evolving concepts in desensitization. Clin Transpl. 2013:285–292.
Jordan SC, Vo A, Lai CH, et al. Defining the benefits of desensitization therapy. Transplantation. 2013;95:e31–e32.
Dyer PA, Taylor CJ. Renal transplantation without a pre-transplant crossmatch. Transplantation. 2000;69:460–461.
Arnold AN, Rahman A, Balazy M, et al. Published HLA-DQA1 associations on DRB1-DQB1 haplotypes predict the flow cytometry crossmatch (FCXM) in a retransplant kidney recipient with dqa1 antibody: implications for listing unacceptable antigens. Hum Immunol. 2012;73:43.
Warren DS, Montgomery RA. Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange. Immunol Res. 2010;47:257–264.
Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation. 2008;86:820–825.
Montgomery RA, Warren DS, Segev DL, et al. HLA incompatible renal transplantation. Curr Opin Organ Transplant. 2012;17:386–392.
Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant. 2010;10:449–457.
Holechek MJ, Hiller JM, Paredes M, et al. Expanding the living organ donor pool: positive crossmatch and ABO incompatible renal transplantation. Nephrol Nurs J. 2003;30:195–204.
Dean PG, Gloor JM, Stegall MD. Conquering absolute contraindications to transplantation: positive-crossmatch and ABO-incompatible kidney transplantation. Surgery. 2005;137:269–273.
Tellis VA, Matas AJ, Senitzer D, et al. Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody. Transplantation. 1989;47:127–129.
Koka P, Cecka JM. Sensitization and crossmatching in renal transplantation. Clin Transpl. 1989:379–390.
Duquesnoy RJ, Takemoto S, de Lange P, et al. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival. Transplantation. 2003;75:884–889.
Duquesnoy RJ, Marrari M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol. 2002;63:353–363.
Duquesnoy RJ, Howe J, Takemoto S. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation. 2003;75:889–897.
Doxiadis II, Claas FH. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both. Curr Opin Organ Transplant. 2009;14:410–413.
Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346–351.
Schinstock C, Dean PG, Li H, et al. Desensitization in the era of kidney paired donation: the Mayo Foundation 3-site experience. Clin Transpl. 2013:235–239.
Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant. 2007;7:402–407.
Jordan SC, Vo A, Tyan D, et al. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc. 2006;117:199–211; discussion 211.
Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003;76:631–636.
Jordan S. IVIG vs. plasmapheresis for desensitization: which is better? Am J Transplant. 2006;6:1510–1511.
Heidt S, Roelen DL, Vergunst M, et al. Bortezomib affects the function of human B cells: possible implications for desensitization protocols. Clin Transpl. 2009:387–392.
Glotz D, Haymann JP, Niaudet P, et al. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc. 1995;27:1038–1039.
Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2:758–760.
Garonzik Wang JM, Montgomery RA, Kucirka LM, et al. Incompatible live-donor kidney transplantation in the United States: results of a national survey. Clin J Am Soc Nephrol. 2011;6:2041–2046.
Sharif A, Zachary AA, Hiller J, et al. Rescue kidney paired donation as emergency salvage for failed desensitization. Transplantation. 2012;93:e27–e29.
Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant. 2008;8:133–143.
Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation. 2004;78:221–227.
Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation. 2014;98:857–863.
Wolff RF, Moons KGM, Riley RD, et al.; PROBAST Group†. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170:51–58.
Al-Otaibi T, Gheith O, Mosaad A, et al. Human leukocyte antigen-DR mismatched pediatric renal transplant: patient and graft outcome with different kidney donor sources. Exp Clin Transplant. 2015;13 Suppl 1:117–123.
Ali H, Shaaban A, Murtaza A, et al. Effect of long-term, low-dose aspirin therapy on renal graft function. Exp Clin Transplant. 2017;15:400–404.
Badwal S, Kumar A, Hooda AK, et al. Immuno-histological assessment of sub-clinical acute and borderline rejection in renal allograft recipients: Data from a transplant center in India. Saudi J Kidney Dis Transpl. 2015;26:1232–1240.
Bloom RD, Bromberg JS, Poggio ED, et al.; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28:2221–2232.
Campos A, Malheiro J, Tafulo S, et al. Increase of allosensitization after a kidney graft failure: Predictors and effect on retransplantation outcomes. Nefrologia. 2017;37:397–405.
Carmellini M, Garcia V, Wang Z, et al. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. J Nephrol. 2015;28:633–639.
Casey MJ, Wen X, Rehman S, et al. Rethinking the advantage of zero-HLA mismatches in unrelated living donor kidney transplantation: implications on kidney paired donation. Transpl Int. 2015;28:401–409.
Chand S, Atkinson D, Collins C, et al. The spectrum of renal allograft failure. PLoS One. 2016;11:e0162278.
Chenouard A, Chesneau M, Bui Nguyen L, et al. Renal operational tolerance is associated with a defect of blood Tfh cells that exhibit impaired B cell help. Am J Transplant. 2017;17:1490–1501.
Chopra B, Sureshkumar KK. Human leukocyte antigen mismatch and steroid maintenance in kidney transplantation. Transplant Proc. 2015;47:2852–2854.
Cippà PE, Schiesser M, Ekberg H, et al. Risk stratification for rejection and infection after kidney transplantation. Clin J Am Soc Nephrol. 2015;10:2213–2220.
Côté JM, Zhang X, Dahhou M, et al. The impact of repeated mismatches in kidney transplantations performed after nonrenal solid organ transplantation. Am J Transplant. 2018;18:238–244.
Cunningham KC, Hager DR, Fischer J, et al. Single-dose basiliximab induction in low-risk renal transplant recipients. Pharmacotherapy. 2016;36:823–829.
de Sandes-Freitas TV, Felipe CR, Aguiar WF, et al. Prolonged delayed graft function is associated with inferior patient and kidney allograft survivals. PLoS One. 2015;10:e0144188.
Ducloux D, Courivaud C, Bamoulid J, et al. Alloimmune responses and atherosclerotic disease after kidney transplantation. Transplantation. 2015;99:220–225.
Everly MJ, Briley KP, Haisch CE, et al. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study. Transpl Int. 2017;30:566–578.
Ferrandiz I, Congy-Jolivet N, Del Bello A, et al. Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies. Am J Transplant. 2016;16:2661–2669.
Fichtner A, Süsal C, Schröder C, et al. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients. Nephrol Dial Transplant. 2018;33:1065–1072.
García-Carro C, Dörje C, Åsberg A, et al. Inflammation in early kidney allograft surveillance biopsies with and without associated tubulointerstitial chronic damage as a predictor of fibrosis progression and development of de novo donor specific antibodies. Transplantation. 2017;101:1410–1415.
Gatault P, Bertrand D, Büchler M, et al. Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation. Transpl Int. 2016;29:41–50.
Giral M, Renaudin K, Naesens M, et al. The 1-year renal biopsy index: a scoring system to drive biopsy indication at 1-year post-kidney transplantation. Transpl Int. [Epub ahead of print. June 12, 2018]. doi: 10.1111/tri.13290
doi: 10.1111/tri.13290
Gonzales MM, Bentall A, Kremers WK, et al. Predicting individual renal allograft outcomes using risk models with 1-year surveillance biopsy and alloantibody data. J Am Soc Nephrol. 2016;27:3165–3174.
Goryainov VA, Kaabak MM, Babenko NN, et al. Predictors of the results of kidney transplantation from living-related donors. Article in Russian. Khirurgiia (Mosk). 2015:43–47.
Goumard A, Sautenet B, Bailly E, et al. Increased risk of rejection after basiliximab induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies - a retrospective study. Transpl Int. 2019;32:820–830.
Halleck F, Khadzhynov D, Liefeldt L, et al. Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching? Nephrol Dial Transplant. 2016;31:2143–2149.
Helanterä I, Räihä J, Finne P, et al. Early failure of kidney transplants in the current era-a national cohort study. Transpl Int. 2018;31:880–886.
Hellemans R, Hazzan M, Durand D, et al. Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study. Am J Transplant. 2015;15:1923–1932.
Hernandez-Rivera JCH, Gonzalez-Ramos J, Perez-Lopez MJ, et al. Dysfunction and rejection in kidney transplant associated with haplotypes. Gac Med Bilbao. 2018;115:77–82.
Jackson-Spence F, Gillott H, Tahir S, et al. Balancing risks for older kidney transplant recipients in the contemporary era: a single-centre observational study. Eur Geriatr Med. 2017;8:42–47.
Kaltenborn A, Nolte A, Schwager Y, et al. Identification of patients at risk for renal impairment after living donor kidney transplantation. Langenbecks Arch Surg. 2016;401:1219–1229.
Khadzhynov D, Halleck F, Lehner L, et al. Immunologic long-term outcomes of living-related kidney transplantations depending on the donor-recipient relationship. Transplant Proc. 2017;49:2265–2268.
Kim KH, Jung HY, Choi JY, et al. HLA gene dosage effect on renal allograft survival. Transplant Proc. 2015;47:635–639.
Kousoulas L, Vondran FW, Syryca P, et al. Risk-adjusted analysis of relevant outcome drivers for patients after more than two kidney transplants. J Transplant. 2015;2015:712049.
Kozakowski N, Herkner H, Eskandary F, et al. An integrative approach for the assessment of peritubular capillaritis extent and score in low-grade microvascular inflammation-associations with transplant glomerulopathy and graft loss. Nephrol Dial Transplant. 2019;34:166–174.
Kramer C, Heidt S, Claas FHJ. Towards the identification of the relative immunogenicity of individual HLA antibody epitopes. Hum Immunol. 2019;80:218–220.
Lan JH, Gjertson D, Zheng Y, et al.; DeKAF Investigators. Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction. Am J Transplant. 2018;18:2934–2944.
Leeaphorn N, Pena JRA, Thamcharoen N, et al. HLA-DQ mismatching and kidney transplant outcomes. Clin J Am Soc Nephrol. 2018;13:763–771.
Lesage J, Noël R, Lapointe I, et al. Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy. Transplantation. 2015;99:69–76.
Lim WH, Chapman JR, Coates PT, et al. HLA-DQ mismatches and rejection in kidney transplant recipients. Clin J Am Soc Nephrol. 2016;11:875–883.
Lim WH, Chapman JR, Wong G. Peak panel reactive antibody, cancer, graft, and patient outcomes in kidney transplant recipients. Transplantation. 2015;99:1043–1050.
Malheiro J, Santos S, Tafulo S, et al. Correlations between donor-specific antibodies and non-adherence with chronic active antibody-mediated rejection phenotypes and their impact on kidney graft survival. Hum Immunol. 2018;79:413–423.
Mesnard L, Muthukumar T, Burbach M, et al. Exome sequencing and prediction of long-term kidney allograft function. PLoS Comput Biol. 2016;12:e1005088.
Monteverde ML, Chaparro A, Goldberg J, et al. Donor-specific anti-HLA antibodies in pediatric renal transplant recipients with creeping creatinine: prevalence, histological correlations, and impact on patient and graft survival. Pediatr Transplant. 2015;19:684–690.
Nabokow A, Dobronravov VA, Khrabrova M, et al. Long-term kidney allograft survival in patients with transplant glomerulitis. Transplantation. 2015;99:331–339.
Nehus EJ, Liu C, Lu B, et al. Graft survival of pediatric kidney transplant recipients selected for de novo steroid avoidance-a propensity score-matched study. Nephrol Dial Transplant. 2017;32:1424–1431.
Opelz G, Döhler B, Middleton D, et al.; A Collaborative Transplant Study Report. HLA matching in pediatric kidney transplantation: HLA poorly matched living donor transplants versus HLA well-matched deceased donor transplants. Transplantation. 2017;101:2789–2792.
Paoletti E, Bussalino E, Bellino D, et al. Early interstitial macrophage infiltration with mild dysfunction is associated with subsequent kidney graft loss. Clin Transplant. 2019;33:e13579.
Parajuli S, Joachim E, Alagusundaramoorthy S, et al. Subclinical antibody-mediated rejection after kidney transplantation: treatment outcomes. Transplantation. 2019;103:1722–1729.
Park WY, Paek JH, Jin K, et al. Differences in pathologic features and graft outcomes of rejection on kidney transplant. Transplant Proc. 2019;51:2655–2659.
Patel SJ, Kuten SA, Knight RJ, et al. Incidence and factors associated with de novo DSA after BK viremia in renal transplant recipients. Clin Transpl. 2016;32:103–109.
Patel SJ, Suki WN, Loucks-DeVos J, et al. Disparate rates of acute rejection and donor-specific antibodies among high-immunologic risk renal transplant subgroups receiving antithymocyte globulin induction. Transpl Int. 2016;29:897–908.
Pearl MH, Grotts J, Rossetti M, et al. Cytokine profiles associated with angiotensin II type 1 receptor antibodies. Kidney Int Rep. 2019;4:541–550.
Redfield RR, Scalea JR, Zens TJ, et al. The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. Nephrol Dial Transplant. 2016;31:1746–1753.
Redfield RR, Scalea JR, Zens TJ, et al. Predictors and outcomes of delayed graft function after living-donor kidney transplantation. Transpl Int. 2016;29:81–87.
Rodrigues S, Escoli R, Eusébio C, et al. A survival analysis of living donor kidney transplant. Transplant Proc. 2019;51:1575–1578.
Ruck JM, Jackson AM, Massie AB, et al. Temporal changes in the impact of HLA mismatching among pediatric kidney transplant recipients. Transplantation. 2019;103:1267–1271.
Sai K, Omoto K, Shimizu T, et al. The impact of C4d-negative acute antibody-mediated rejection on short-term prognosis among kidney transplant recipients. Nephrology (Carlton). 2015;20 Suppl 2:16–19.
Schwager Y, Littbarski SA, Nolte A, et al. Prediction of three-year mortality after deceased donor kidney transplantation in adults with pre-transplant donor and recipient variables. Ann Transplant. 2019;24:273–290.
Sharma A, Cherukuri A, Mehta RB, et al. High calcineurin inhibitor intrapatient variability is associated with renal allograft inflammation, chronicity, and graft loss. Transplant Direct. 2019;5:e424.
Shin S, Kim YH, Choi BH, et al. Long-term impact of human leukocyte antigen mismatches combined with expanded criteria donor on allograft outcomes in deceased donor kidney transplantation. Clin Transplant. 2015;29:44–51.
Slatinska J, Slavcev A, Honsova E, et al. Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study. HLA. 2018;92 Suppl 2:47–50.
Stepkowski SM, Mierzejewska B, Fumo D, et al. The 6-year clinical outcomes for patients registered in a multiregional United States Kidney Paired Donation program - a retrospective study. Transpl Int. 2019;32:839–853.
Sureshkumar KK, Chopra B. Induction type and outcomes in HLA-DR mismatch kidney transplantation. Transplant Proc. 2019;51:1796–1800.
Tabibzadeh N, Glowacki F, Frimat M, et al. Long-term outcome after early cyclosporine withdrawal in kidney transplantation: ten years after. Clin Transplant. 2016;30:1480–1487.
Tinckam KJ, Rose C, Hariharan S, et al. Re-examining risk of repeated HLA mismatch in kidney transplantation. J Am Soc Nephrol. 2016;27:2833–2841.
Tipjaiaue P, Ingsathit A, Kantachuvesiri P, et al. Outcome of pretransplantation therapeutic plasma exchange in highly sensitized deceased-donor kidney transplant recipients. Transplant Proc. 2017;49:1249–1255.
Trnka P, McTaggart SJ, Francis A. The impact of donor/recipient age difference and HLA mismatch on graft outcome in pediatric kidney transplantation. Pediatr Transplant. 2018;22:e13265.
Veras de Sandes-Freitas T, Gomes Ramalho de Oliveira J, Loiola de Alencar Dantas G, et al. Clinical characteristics and outcomes of kidney transplantation under urgency priority condition. Nephron. 2019;142:98–105.
Vinson AJ, Kiberd BA, Davis RB, et al. Nonimmunologic donor-recipient pairing, HLA matching, and graft loss in deceased donor kidney transplantation. Transplant Direct. 2019;5:e414.
Wan Q, Wu D, Xiao X. An analysis of cytokine gene polymorphisms on acute rejection in renal recipients. Acta Medica Mediterranea. 2018;34:47.
Wasik HL, Pruette CS, Ruebner RL, et al. A donor risk index for graft loss in pediatric living donor kidney transplantation. Am J Transplant. 2019;19:2775–2782.
Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant. 2015;15:2921–2930.
Williams RC, Opelz G, McGarvey CJ, et al. The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors. Transplantation. 2016;100:1094–1102.
Williams RC, Opelz G, Weil EJ, et al. The risk of transplant failure with HLA mismatch in first adult kidney allografts 2: living donors, summary, guide. Transplant Direct. 2017;3:e152.
Williams RC, West LJ, Opelz G. The risk of failure with HLA mismatch and recipient age in first pediatric (<18 years) kidney transplants. Transplant Direct. 2018;4:e365.
Wong G, Chakera A, Chapman JR, et al. Cytomegalovirus and cancer after kidney transplantation: role of the human leukocyte antigen system? Transpl Infect Dis. 2017;19.
Zhang H, Wei Y, Liu L, et al. Different risk factors for graft survival between living-related and deceased donor kidney transplantation. Transplant Proc. 2018;50:2416–2420.
Lemoine M, Titeca Beauport D, Lobbedez T, et al. Risk factors for early graft failure and death after kidney transplantation in recipients older than 70 years. Kidney Int Rep. 2019;4:656–666.
Abuhelaiqa E, Friedlander R, Aull M, et al. Acute rejection, kidney allograft function, and graft survival in patients with circulating pre-transplant IgG antibodies directed against donor HLA-A, -B, or -C locus determined antigens. Clin Transpl. 2016;32:83–91.
Alagoz S, Seyahi N. Frequency of human leukocyte antigens and donor specific antibodies in long-term living donor kidney transplantation. Transplant Proc. 2019;51:2302–2307.
Alkadi MM, Kim J, Aull MJ, et al. Kidney allograft failure in the steroid-free immunosuppression era: a matched case-control study. Clin Transplant. 2017;31.
Alpay N, Özçelik Ü, Eren E, et al. Renal transplantation in high immunological risk patients: a single-center experience. Transplant Proc. 2019;51:2298–2301.
Amrouche L, Aubert O, Suberbielle C, et al. Long-term outcomes of kidney transplantation in patients with high levels of preformed DSA: the Necker High-Risk Transplant Program. Transplantation. 2017;101:2440–2448.
Arnold ML, Bach C, Heinemann FM, et al. Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: correlation with graft survival. Int J Immunogenet. 2018;45:95–101.
Aubert O, Loupy A, Hidalgo L, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017;28:1912–1923.
Babu A, Andreou A, Briggs D, et al. Clinical relevance of donor-specific IgM antibodies in HLA incompatible renal transplantation: a retrospective single-center study. Clin Transpl. 2016;32:173–179.
Bachelet T, Martinez C, Del Bello A, et al. Deleterious impact of donor-specific anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation. Transplantation. 2016;100:159–166.
Barnes JCH, Goodyear SJ, Imray CEA, et al. Kidney retransplantation from HLA-incompatible living donors: a single-center study of 3rd/4th transplants. Clin Transplant. 2017;31:e13104.
Bray RA, Gebel HM, Townsend R, et al. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: post hoc analyses of BENEFIT and BENEFIT-EXT. Am J Transplant. 2018;18:1774–1782.
Bray RA, Gebel HM, Townsend R, et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant. 2018;18:1783–1789.
Brick C, Atouf O, Essakalli M. Immunological monitoring in kidney transplantation: 13 years experience of a Moroccan histocompatibility laboratory. Article in French. Transfus Clin Biol. 2016;23:86–94.
Bynum JP, Zachary A, Ness PM, et al. Transfusion of leukoreduced blood products and risk of antibody-mediated rejection of renal allografts. Transfusion. 2018;58:1951–1957.
Castro A, Malheiro J, Tafulo S, et al. Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: a case-control study. HLA. 2017;90:267–275.
Chung BH, Kim JH, Choi BS, et al. Clinical significance of the presence of anti-human leukocyte antigen-donor specific antibody in kidney transplant recipients with allograft dysfunction. Korean J Intern Med. 2018;33:157–167.
Colak H, Ersan S, Tanrisev M, et al. Relationship of interleukin-10 and transforming growth factor-β levels with short-term graft function after kidney transplantation. Transplant Proc. 2015;47:1360–1363.
Cosio FG, El Ters M, Cornell LD, et al. Changing kidney allograft histology early posttransplant: prognostic implications of 1-year protocol biopsies. Am J Transplant. 2016;16:194–203.
Couzi L, Manook M, Perera R, et al. Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations. Transpl Int. 2015;28:1205–1215.
Crespo E, Cravedi P, Martorell J, et al. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients. Kidney Int. 2017;92:201–213.
Dabare D, Kassimatis T, Hodson J, et al. Outcomes in third and fourth kidney transplants based on the type of donor. Transplantation. 2019;103:1494–1503.
Daniëls L, Naesens M, Bosmans JL, et al. The clinical significance of epitope mismatch load in kidney transplantation: a multicentre study. Transpl Immunol. 2018;50:55–59.
de Castro MCR, Barbosa EA, Souza RP, et al. The kinetics of anti-HLA antibodies in the first year after kidney transplantation: in whom and when should they be monitored? J Transplant. 2018;2018:8316860.
de Sandes-Freitas TV, Felipe CR, Campos ÉF, et al. Subclinical lesions and donor-specific antibodies in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen followed by early conversion to sirolimus. Transplantation. 2015;99:2372–2381.
de Sousa MV, Gonçalez AC, Zollner RL, et al. Effect of preformed or de novo anti-HLA antibodies on function and graft survival in kidney transplant recipients. Ann Transplant. 2018;23:457–466.
Dean PG, Park WD, Cornell LD, et al. Early subclinical inflammation correlates with outcomes in positive crossmatch kidney allografts. Clin Transplant. 2016;30:925–933.
Dello Strologo L, Murer L, Guzzo I, et al. Renal transplantation in sensitized children and young adults: a nationwide approach. Nephrol Dial Transplant. 2017;32:191–195.
Demirok A, Ranzijn C, Lardy J, et al. Evaluation of the current post-transplantation human leukocyte antigen antibody screening in pediatric renal transplant recipients. Pediatr Transplant. 2019;23:e13338.
Do Nguyen HT, Wong G, Chapman JR, et al. The association between broad antigen HLA mismatches, eplet HLA mismatches and acute rejection after kidney transplantation. Transplant Direct. 2016;2:e120.
Eskandary F, Bond G, Kozakowski N, et al. Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study. Transplantation. 2017;101:631–641.
Fernández C, Calvo M, Leite N, et al. Kidney transplantation from HLA-incompatible live donors: Efficiency and outcome of 32 patients after desensitisation. Nefrologia. 2017;37:638–645.
Friebus-Kardash J, Wilde B, Keles D, et al. Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. Transpl Immunol. 2018;47:10–17.
Gandolfini I, Crespo E, Baweja M, et al. Impact of preformed T-cell alloreactivity by means of donor-specific and panel of reactive T cells (PRT) ELISPOT in kidney transplantation. PLoS One. 2018;13:e0200696.
Geneugelijk K, Niemann M, Drylewicz J, et al. PIRCHE-II is related to graft failure after kidney transplantation. Front Immunol. 2018;9:321.
Gimeno J, Redondo D, Pérez-Sáez MJ, et al. Impact of the Banff 2013 classification on the diagnosis of suspicious versus conclusive late antibody-mediated rejection in allografts without acute dysfunction. Nephrol Dial Transplant. 2016;31:1938–1946.
Girerd S, Schikowski J, Girerd N, et al. Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014. BMC Nephrol. 2018;19:232.
Goubella A, Broeders N, Racapé J, et al. Patient and graft outcome in current era of immunosuppression: a single centre pilot study. Acta Clin Belg. 2015;70:23–29.
Green H, Nesher E, Aizner S, et al. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients. Clin Transplant. 2019;33:e13562.
Gupta A, Murillo D, Yarlagadda SG, et al. Donor-specific antibodies present at the time of kidney transplantation in immunologically unmodified patients increase the risk of acute rejection. Transpl Immunol. 2016;37:18–22.
Habets THPM, Hepkema BG, Kouprie N, et al. The prevalence of antibodies against the HLA-DRB3 protein in kidney transplantation and the correlation with HLA expression. PLoS One. 2018;13:e0203381.
Haller J, Wehmeier C, Hönger G, et al. Differential impact of delayed graft function in deceased donor renal transplant recipients with and without donor-specific HLA-antibodies. Transplantation. 2019;103:e273–e280.
Heidt S, Haasnoot GW, van Rood JJ, et al. Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients. Kidney Int. 2018;93:491–500.
Heidt S, Haasnoot GW, Witvliet MD, et al. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. Am J Transplant. 2019;19:2926–2933.
Higgins R, Lowe D, Daga S, et al. Pregnancy-induced HLA antibodies respond more vigorously after renal transplantation than antibodies induced by prior transplantation. Hum Immunol. 2015;76:546–552.
Hirt-Minkowski P, Ho J, Gao A, et al. Prediction of long-term renal allograft outcome by early urinary CXCL10 chemokine levels. Transplant Direct. 2015;1:e31.
Hörmann M, Dieplinger G, Rebellato LM, et al. Incidence and impact of anti-HLA-DP antibodies in renal transplantation. Clin Transplant. 2016;30:1108–1114.
Idris MA, Hossain A, Muntasir MA, et al. Outcome of recipients of human leukocyte antigen incompatible kidney transplants who underwent desensitization at King Fahad Specialist Hospital, Dammam, Saudi Arabia. Saudi J Kidney Dis Transpl. 2017;28:499–506.
Iwami D, Hotta K, Sasaki H, et al. Highly immunogenic DQB1 mismatch eplets are associated with development of chronic active antibody-mediated rejection: a first report from Japan. Transplant Proc. 2017;49:84–87.
Ixtlapale-Carmona X, Arvizu A, De-Santiago A, et al. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies. Transpl Immunol. 2018;46:8–13.
Jackson AM, Kraus ES, Orandi BJ, et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int. 2015;87:409–416.
Johnson CP, Schiller JJ, Zhu YR, et al. Renal transplantation with final allocation based on the virtual crossmatch. Am J Transplant. 2016;16:1503–1515.
Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017;377:442–453.
Jung HY, Cho SY, Choi JY, et al. Comparison of transplant outcomes for low-level and standard-level tacrolimus at different time points after kidney transplantation. J Korean Med Sci. 2019;34:e103.
Kahwaji J, Jordan SC, Najjar R, et al. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Int. 2016;29:1276–1285.
Kamburova EG, Wisse BW, Joosten I, et al. Pretransplant C3d-fixing donor-specific anti-HLA antibodies are not associated with increased risk for kidney graft failure. J Am Soc Nephrol. 2018;29:2279–2285.
Kamburova EG, Wisse BW, Joosten I, et al. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. Am J Transplant. 2018;18:2274–2284.
Kamoun M, McCullough KP, Maiers M, et al. HLA amino acid polymorphisms and kidney allograft survival. Transplantation. 2017;101:e170–e177.
Kannabhiran D, Lee J, Schwartz JE, et al. Characteristics of circulating donor human leukocyte antigen-specific immunoglobulin G Antibodies predictive of acute antibody-mediated rejection and kidney allograft failure. Transplantation. 2015;99:1156–1164.
Khovanova N, Daga S, Shaikhina T, et al. Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure. Transpl Int. 2015;28:1405–1415.
Kim YC, Yu MY, Lee JP, et al. The effect of desensitization therapy in kidney transplantation. Clin Exp Nephrol. 2018;22:179–187.
Kishikawa H, Kinoshita T, Hashimoto M, et al. Class II HLA eplet mismatch is a risk factor for de novo donor-specific antibody development and antibody-mediated rejection in kidney transplantation recipients. Transplant Proc. 2018;50:2388–2391.
Kolonko A, Bzoma B, Giza P, et al. The pre-transplant drop in panel-reactive antibodies titer evaluated using complement-dependent cytotoxicity (PRA-CDC) and the risk of early acute rejection in sensitized kidney transplant recipients. Medicina (Kaunas). 2018;54:E66.
Kosmoliaptsis V, Mallon DH, Chen Y, et al. Alloantibody responses after renal transplant failure can be better predicted by donor-recipient HLA amino acid sequence and physicochemical disparities than conventional HLA matching. Am J Transplant. 2016;16:2139–2147.
Kumar D, Fattah H, Kimball PM, et al. Post-transplant desensitization for deceased donor kidney transplant recipients: a single center experience. Clin Transpl. 2016;32:143–151.
Kupatawintu P, Tatawatorn A, Premasathian N, et al. Association between flow cytometric crossmatching and graft survival in Thai cadaveric-donor kidney transplantation. Asian Pac J Allergy Immunol. 2016;34:86–93.
Kwon H, Kim YH, Choi JY, et al. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches. Clin Transplant. 2018;32:e13266.
Kwon H, Kim YH, Choi JY, et al. Analysis of 4000 kidney transplantations in a single center: across immunological barriers. Medicine (Baltimore). 2016;95:e4249.
Kwon H, Kim YH, Kim JY, et al. The results of HLA-incompatible kidney transplantation according to pre-transplant crossmatch tests: donor-specific antibody as a prominent predictor of acute rejection. Clin Transplant. 2019;33:e13533.
Laftavi MR, Pankewycz O, Feng L, et al. Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients. Immunol Invest. 2015;44:373–384.
Lasmar MF, Dutra RS, Nogueira-Machado JA, et al. Effects of immunotherapy induction on outcome and graft survival of kidney-transplanted patients with different immunological risk of rejection. BMC Nephrol. 2019;20:314.
Lee DR, Kim BC, Kim JP, et al. C3d-binding donor-specific HLA antibody is associated with a high risk of antibody-mediated rejection and graft loss in stable kidney transplant recipients: a single-center cohort study. Transplant Proc. 2018;50:3452–3459.
Lee J, Kim DG, Kim BS, et al. Early hospital readmissions after ABO- or HLA- incompatible living donor kidney transplantation. Sci Rep. 2019;9:3246.
Lee KW, Park JB, Cho CW, et al. The impact of donor-specific anti-human leukocyte antigen (HLA) antibody rebound on the risk of antibody mediated rejection in sensitized kidney transplant recipients. Ann Transplant. 2017;22:166–176.
Lefaucheur C, Gosset C, Rabant M, et al. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. Am J Transplant. 2018;18:377–390.
Lefaucheur C, Viglietti D, Bouatou Y, et al. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int. 2019;96:189–201.
Lefaucheur C, Viglietti D, Hidalgo LG, et al. Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment. J Am Soc Nephrol. 2018;29:620–635.
Lobashevsky A, Goggins W, Rosner K, et al. Immunogenicity of class I HLA but not preformed low MFI donor specific antibodies correlates with outcomes after first renal transplantation. Transpl Immunol. 2017;43-44:42–48.
Lohéac C, Aubert O, Loupy A, et al. Identifying the specific causes of kidney allograft loss: a population-based study. Article in French. Nephrol Ther. 2018;14 Suppl 1:S39–S50.
Louis K, Hertig A, Taupin JL, et al. Markers of graft microvascular endothelial injury may identify harmful donor-specific anti-HLA antibodies and predict kidney allograft loss. Am J Transplant. 2019;19:2434–2445.
Luque S, Lúcia M, Melilli E, et al. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation. Am J Transplant. 2019;19:368–380.
Malfait T, Emonds MP, Daniëls L, et al. HLA class II antibodies at the time of kidney transplantation and cardiovascular outcome: a retrospective cohort study. Transplantation. 2020;104:823–834.
Malheiro J, Santos S, Tafulo S, et al. Detection of complement-binding donor-specific antibodies, not IgG-antibody strength nor C4d status, at antibody-mediated rejection diagnosis is an independent predictor of kidney graft failure. Transplantation. 2018;102:1943–1954.
Malheiro J, Tafulo S, Dias L, et al. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation. Transpl Immunol. 2015;32:66–71.
Malheiro J, Tafulo S, Dias L, et al. Impact on mid-term kidney graft outcomes of pretransplant anti-HLA antibodies detected by solid-phase assays: do donor-specific antibodies tell the whole story? Hum Immunol. 2017;78:526–533.
Malheiro J, Tafulo S, Dias L, et al. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation. Transpl Int. 2017;30:347–359.
Mallon DH, Kling C, Robb M, et al. Predicting humoral alloimmunity from differences in donor and recipient HLA surface electrostatic potential. J Immunol. 2018;201:3780–3792.
Marks WH, Mamode N, Montgomery RA, et al.; C10-001 Study Group. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. Am J Transplant. 2019;19:2876–2888.
Mehta R, Bhusal S, Randhawa P, et al. Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol. Am J Transplant. 2018;18:1710–1717.
Melilli E, Crespo E, Sandoval D, et al. De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring. Transpl Int. 2015;28:1283–1290.
Meneghini M, Melilli E, Martorell J, et al. Combining sensitive crossmatch assays with donor/recipient human leukocyte antigen eplet matching predicts living-donor kidney transplant outcome. Kidney Int Rep. 2018;3:926–938.
Michelen-Gómez E, Ramos R, Ruiz J, et al. A clinical study on cadaveric kidney donors in Puerto Rico and the survival outcome of the grafts: a retrospective study of 187 kidneys from 2009-2011. P R Health Sci J. 2019;38:92–96.
Michielsen LA, Wisse BW, Kamburova EG, et al. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. Nephrol Dial Transplant. 2019;34:1056–1063.
Min JW, Kim KW, Kim BM, et al. Clinical significance of pre- and post-transplant BAFF levels in kidney transplant recipients. PLoS One. 2016;11:e0162964.
Min JW, Lee H, Choi BS, et al. Clinical impact of pre-transplant antibodies against angiotensin II type I receptor and major histocompatibility complex class I-related chain a in kidney transplant patients. Ann Lab Med. 2018;38:450–457.
Molina J, Navas A, Agüera ML, et al. Impact of preformed donor-specific anti-human leukocyte antigen antibody C1q-binding ability on kidney allograft outcome. Front Immunol. 2017;8:1310.
Muramatsu M, Hyodo Y, Sheaff M, et al. Impact of allograft nephrectomy on second renal transplant outcome. Exp Clin Transplant. 2018;16:259–265.
NasrAllah MM, Elalfy MM, Fakhry SA, et al. Impact of adopting routine Luminex-based pretransplant assessment of HLA antibodies on clinical practice and outcomes in kidney transplantation. Transplant Proc. 2019;51:2241–2244.
Novotny M, Hruba P, Vichova P, et al. Isolated v-lesion represents a benign phenotype of vascular rejection of the kidney allograft - a retrospective study. Transpl Int. 2018;31:1153–1163.
Okabe Y, Noguchi H, Miyamoto K, et al. Preformed C1q-binding donor-specific anti-HLA antibodies and graft function after kidney transplantation. Transplant Proc. 2018;50:3460–3466.
Parajuli S, Joachim E, Alagusundaramoorthy S, et al. Donor-specific antibodies in the absence of rejection are not a risk factor for allograft failure. Kidney Int Rep. 2019;4:1057–1065.
Parajuli S, Muth BL, Turk JA, et al. In kidney transplant recipients with a positive virtual crossmatch, high PRA was associated with lower incidence of viral infections. Transplantation. 2016;100:655–661.
Parajuli S, Redfield RR, Astor BC, et al. Outcomes in the highest panel reactive antibody recipients of deceased donor kidneys under the new kidney allocation system. Clin Transplant. 2017;31:e12895.
Passamonti SM, Cannavò A, Espadas de Arias A, et al. Pretransplant single antigen bead-detected HLA antibodies in kidney transplant long-term outcome: a single-center cohort experience. Transplant Proc. 2019;51:707–714.
Peng B, Zhuang Q, Yu M, et al. Comparison of physical crossmatch and virtual crossmatch to identify preexisting donor-specific human leukocyte antigen (HLA) antibodies and outcome following kidney transplantation. Med Sci Monit. 2019;25:952–961.
Peräsaari JP, Kyllönen LE, Salmela KT, et al. Pre-transplant donor-specific anti-human leukocyte antigen antibodies are associated with high risk of delayed graft function after renal transplantation. Nephrol Dial Transplant. 2016;31:672–678.
Pongpirul W, Chancharoenthana W, Pongpirul K, et al. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients. Nephrology (Carlton). 2018;23:169–174.
Ponsirenas RvG, Cazarote HB, Araujo SdA, et al. Anti-HLA donor-specific IgG subclasses and C1q-binding evolution in posttransplant monitoring. Transplant Direct. 2018;4:e385.
Querido S, Weigert A, Adragão T, et al. Intravenous immunoglobulin and rituximab in HLA highly sensitized kidney transplant recipients. Transplant Proc. 2018;50:723–727.
Quintella AHDS, Lasmar MF, Fabreti-Oliveira RA, et al. Delayed graft function, predictive factors, and 7-year outcome of deceased donor kidney transplant recipients with different immunologic profiles. Transplant Proc. 2018;50:737–742.
Redondo-Pachón D, Pérez-Sáez MJ, Mir M, et al. Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes. Hum Immunol. 2018;79:424–431.
Riley AA, Klingman L, Brier ME, et al. In vivo heat inactivation of serum can distinguish false positive cross matches in renal transplants. Int J Artif Organs. 2016;39:63–67.
Salvadé I, Aubert V, Venetz JP, et al. Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation. Hum Immunol. 2016;77:483–489.
Sapir-Pichhadze R, Tinckam K, Quach K, et al. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study. Am J Transplant. 2015;15:137–148.
Scalea JR, Redfield RR, Muth BL, et al. Older kidney transplant patients experience less antibody-mediated rejection: a retrospective study of patients with mild to moderate sensitization. Clin Transplant. 2015;29:1090–1097.
Schaefer SM, Süsal C, Opelz G, et al. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients. HLA. 2016;87:89–99.
Schinstock CA, Bentall AJ, Smith BH, et al. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant. 2019;19:1671–1683.
Schinstock CA, Gandhi M, Cheungpasitporn W, et al. Kidney transplant with low levels of DSA or low positive B-flow crossmatch: an underappreciated option for highly sensitized transplant candidates. Transplantation. 2017;101:2429–2439.
Schwaiger E, Eskandary F, Kozakowski N, et al. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection. Nephrol Dial Transplant. 2016;31:1342–1351.
Senev A, Coemans M, Lerut E, et al. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome. Am J Transplant. 2019;19:763–780.
Senev A, Lerut E, Van Sandt V, et al. Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. Am J Transplant. 2019;19:3100–3113.
Shaffer D, Feurer ID, Crowe D, et al. Early and sustained reduction in donor-specific antibodies in desensitized living donor kidney transplant recipients: a 3-year prospective study. Transplant Direct. 2016;2:e62.
Shaikhina T, Lowe D, Daga S, et al. Decision tree and random forest models for outcome prediction in antibody incompatible kidney transplantation. Biomed Signal Process Control. 2019;52:456–462.
Sharma A, King A, Kumar D, et al. Perioperative desensitization improves outcomes among crossmatch positive recipients of deceased donor renal transplants. Prog Transplant. 2016;26:157–161.
Sinangil A, Ucar ZA, Koc Y, et al. Outcome of desensitization therapy in immunologically high-risk kidney transplantation: single-center experience. Transplant Proc. 2019;51:2268–2273.
Snanoudj R, Kamar N, Cassuto E, et al. Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. Kidney Int. 2019;95:1471–1485.
Süsal C, Döhler B, Ruhenstroth A, et al.; A Collaborative Transplant Study Report. Donor-specific antibodies require preactivated immune system to harm renal transplant. Ebiomedicine. 2016;9:366–371.
Taner T, Park WD, Stegall MD. Unique molecular changes in kidney allografts after simultaneous liver-kidney compared with solitary kidney transplantation. Kidney Int. 2017;91:1193–1202.
Thammanichanond D, Wiwattanathum P, Mongkolsuk T, et al. Role of pretransplant complement-fixing donor-specific antibodies identified by C1q assay in kidney transplantation. Transplant Proc. 2016;48:756–760.
Tian J, Li D, Alberghini TV, et al. Pre-transplant low level HLA antibody shows a composite poor outcome in long-term outcome of renal transplant recipients. Ren Fail. 2015;37:198–202.
Uffing A, Hidalgo LG, McMullan C, et al. Preformed donor-specific antibodies against HLA class II and graft outcomes in deceased-donor kidney transplantation. Transplant Direct. 2019;5:e446.
Ulloa CE, Anglicheau D, Snanoudj R, et al. Conversion from calcineurin inhibitors to belatacept in HLA-sensitized kidney transplant recipients with low-level donor-specific antibodies. Transplantation. 2019;103:2150–2156.
Ushigome H, Harada S, Nakao M, et al. Living-donor kidney transplantation with existing anti-donor specific antibodies at a Japanese single center. Transplant Proc. 2015;47:612–616.
van den Bosch TPP, Hilbrands LB, Kraaijeveld R, et al. Pretransplant numbers of CD16+ monocytes as a novel biomarker to predict acute rejection after kidney transplantation: a pilot study. Am J Transplant. 2017;17:2659–2667.
Viglietti D, Bouatou Y, Kheav VD, et al. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney Int. 2018;94:773–787.
Viglietti D, Loupy A, Aubert O, et al. Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection. J Am Soc Nephrol. 2018;29:606–619.
Viglietti D, Loupy A, Vernerey D, et al. Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J Am Soc Nephrol. 2017;28:702–715.
Vimal M, Chacko MP, Basu G, et al. Correlation of pretransplant donor-specific antibody assay using Luminex crossmatch with graft outcome in renal transplant patients. Indian J Nephrol. 2017;27:347–352.
Visentin J, Marroc M, Guidicelli G, et al. Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation. Clin Transplant. 2015;29:393–402.
Vo AA, Aubert O, Haas M, et al. Clinical relevance of posttransplant DSAs in patients receiving desensitization for HLA-incompatible kidney transplantation. Transplantation. 2019;103:2666–2674.
Vo AA, Sinha A, Haas M, et al. Factors predicting risk for antibody-mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation. 2015;99:1423–1430.
Wang N, Li W, Zhang S. Effect of pre-transplant donor specific antibody on antibody-mediated rejection and graft dysfunction. Article in Chinese. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016;41:513–519.
Wehmeier C, Amico P, Hirt-Minkowski P, et al. Acute rejection phenotypes in the current era of immunosuppression: a single-center analysis. Transplant Direct. 2017;3:e136.
Wehmeier C, Hönger G, Cun H, et al. Donor specificity but not broadness of sensitization is associated with antibody-mediated rejection and graft loss in renal allograft recipients. Am J Transplant. 2017;17:2092–2102.
Wehmeier C, Karahan GE, Krop J, et al.; Swiss Transplant Cohort Study. Donor-specific B cell memory in alloimmunized kidney transplant recipients: first clinical application of a novel method. Transplantation. 2020;104:1026–1032.
Wiebe C, Gareau AJ, Pochinco D, et al. Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival. Am J Transplant. 2017;17:703–711.
Wiebe C, Kosmoliaptsis V, Pochinco D, et al. HLA-DR/DQ molecular mismatch: a prognostic biomarker for primary alloimmunity. Am J Transplant. 2019;19:1708–1719.
Wiebe C, Kosmoliaptsis V, Pochinco D, et al. A comparison of HLA molecular mismatch methods to determine HLA immunogenicity. Transplantation. 2018;102:1338–1343.
Wiebe C, Nevins TE, Robiner WN, et al. The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival. Am J Transplant. 2015;15:2197–2202.
Wiebe C, Rush DN, Nevins TE, et al. Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol. 2017;28:3353–3362.
Willicombe M, Rizzello A, Goodall D, et al. Risk factors and outcomes of delayed graft function in renal transplant recipients receiving a steroid sparing immunosuppression protocol. World J Transplant. 2017;7:34–42.
Wisse BW, Kamburova EG, Joosten I, et al. Toward a sensible single-antigen bead cutoff based on kidney graft survival. Transplantation. 2019;103:789–797.
Wittenbrink N, Herrmann S, Blazquez-Navarro A, et al. A novel approach reveals that HLA class 1 single antigen bead-signatures provide a means of high-accuracy pre-transplant risk assessment of acute cellular rejection in renal transplantation. BMC Immunol. 2019;20:11.
Wiwattanathum P, Ingsathit A, Thammanichanond D, et al. Significance of HLA antibody detected by PRA-bead method in kidney transplant outcomes. Transplant Proc. 2016;48:761–765.
Wu K, Budde K, Schmidt D, et al. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. Clin Transplant. 2016;30:105–117.
Yang CY, Lee CY, Yeh CC, et al. Renal transplantation across the donor-specific antibody barrier: graft outcome and cancer risk after desensitization therapy. J Formos Med Assoc. 2016;115:426–433.
Zecher D, Bach C, Preiss A, et al. Analysis of Luminex-based algorithms to define unacceptable HLA antibodies in CDC-crossmatch negative kidney transplant recipients. Transplantation. 2018;102:969–977.
Zecher D, Bach C, Staudner C, et al. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. Nephrol Dial Transplant. 2017;32:730–737.
Zhang Y, Briggs D, Lowe D, et al. A new data-driven model for post-transplant antibody dynamics in high risk kidney transplantation. Math Biosci. 2017;284:3–11.
Zhao H, Lai X, Lu J, et al. Effect of HLA matching on pediatric renal transplant graft survival in China. Transplant Proc. 2017;49:1291–1293.
Zheng J, Xue W, Jing X, et al. Influence of de novo donor-specific antibody on early renal allograft function recovery. Ren Fail. 2015;37:462–468.
Zhu L, Wang ZQ, Feng H, et al. Strategy and clinical outcome of deceased donor kidney transplantation for presensitized recipients. Article in Chinese. Zhonghua Yi Xue Za Zhi. 2019;99:895–900.
Manook M, Koeser L, Ahmed Z, et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. Lancet. 2017;389:727–734.
Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 2009;6:e1000097.
D’Souza Y, Ferradji A, Saw C, et al. Inaccuracies in epitope repertoire estimations when using multi-locus allele-level HLA genotype imputation tools. HLA. [Epub ahead of print. June 10, 2018]. doi: 10.1111/tan.13307
doi: 10.1111/tan.13307
Engen RM, Jedraszko AM, Conciatori MA, et al. Substituting imputation of HLA antigens for high-resolution HLA typing: evaluation of a multiethnic population and implications for clinical decision making in transplantation. Am J Transplant. 2021;21:344–352.
Senev A, Emonds MP, Van Sandt V, et al. Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation. Am J Transplant. 2020;20:3367–3378.
Tambur AR, Campbell P, Chong AS, et al. Sensitization in Transplantation: Assessment of Risk (STAR) 2019 Working Group meeting report. Am J Transplant. 2020;20:2652–2668.
Tambur AR, Campbell P, Claas FH, et al. Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group meeting report. Am J Transplant. 2018;18:1604–1614.
McCaughan J, Xu Q, Tinckam K. Detecting donor-specific antibodies: the importance of sorting the wheat from the chaff. Hepatobiliary Surg Nutr. 2019;8:37–52.
Valenzuela NM, Askar M, Heidt S, et al. Minimal data reporting standards for serological testing for histocompatibility. Hum Immunol. 2018;79:865–868.
Konvalinka A, Tinckam K. Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol. 2015;26:1489–1502.
Bouquegneau A, Loheac C, Aubert O, et al. Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis. PLoS Med. 2018;15:e1002572.
Clifford Sullivan H, Krummey SM, Gebel HM, et al. Physical crossmatching vs virtual crossmatching: the end of an era? or Why give up a good thing? Hum Immunol. 2020;81:401–406.
Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation. Am J Transplant. 2013;13:3050–3051.
Roufosse C, Simmonds N, Clahsen-van Groningen M, et al. A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation. 2018;102:1795–1814.
Sapir-Pichhadze R, Pintilie M, Tinckam KJ, et al. Survival analysis in the presence of competing risks: the example of waitlisted kidney transplant candidates. Am J Transplant. 2016;16:1958–1966.
Duquesnoy RJ, Marrari M, da M Sousa LC, et al. 16 th IHIW: a website for antibody-defined HLA epitope registry. Int J Immunogenet. 2013;40:54–59.
Duquesnoy RJ, Marrari M, Marroquim MS, et al. Second update of the international registry of HLA epitopes. I. The HLA-ABC epitope database. Hum Immunol. 2019;80:103–106.
Duquesnoy RJ. Update of the HLA class I eplet database in the website based registry of antibody-defined HLA epitopes. Tissue Antigens. 2014;83:382–390.
Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant. 2013;13:3114–3122.
Sapir-Pichhadze R, Zhang X, Ferradji A, et al. Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss. Kidney Int. 2020;97:778–785.
Kramer CSM, Koster J, Haasnoot GW, et al. HLA-EMMA: a user-friendly tool to analyse HLA class I and class II compatibility on the amino acid level. HLA. 2020;96:43–51.
Meszaros M, Niemann M, Ursic-Bedoya J, et al. Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study. Transpl Immunol. 2020;59:101272.
Hamada S, Dumortier J, Thévenin C, et al. Predictive value of HLA matchmaker and PIRCHE-II scores for de novo donor-specific antibody formation after adult and pediatric liver transplantation. Transpl Immunol. 2020;61:101306.
Senev A, Van Loon E, Lerut E, et al. Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies. Kidney Int. 2021;100:401–414.
Kosmoliaptsis V, Sharples LD, Chaudhry AN, et al. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation. 2011;91:183–190.
Kosmoliaptsis V, Dafforn TR, Chaudhry AN, et al. High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol. 2011;72:1049–1059.